CN115969777B - Tetrahydropalmatine-bletilla polysaccharide latex and preparation method thereof - Google Patents
Tetrahydropalmatine-bletilla polysaccharide latex and preparation method thereof Download PDFInfo
- Publication number
- CN115969777B CN115969777B CN202310067982.5A CN202310067982A CN115969777B CN 115969777 B CN115969777 B CN 115969777B CN 202310067982 A CN202310067982 A CN 202310067982A CN 115969777 B CN115969777 B CN 115969777B
- Authority
- CN
- China
- Prior art keywords
- tetrahydropalmatine
- latex
- bletilla polysaccharide
- homogenizing
- bletilla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000126 latex Polymers 0.000 title claims abstract description 69
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 68
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 68
- 150000004676 glycans Chemical class 0.000 title claims abstract description 67
- 239000004816 latex Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims abstract description 28
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 26
- 229920002752 Konjac Polymers 0.000 claims abstract description 21
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 21
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 21
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008117 stearic acid Substances 0.000 claims abstract description 21
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000252 konjac Substances 0.000 claims abstract description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 241001313855 Bletilla Species 0.000 claims abstract description 14
- 235000019823 konjac gum Nutrition 0.000 claims abstract description 10
- 239000003921 oil Substances 0.000 claims abstract description 9
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 239000006228 supernatant Substances 0.000 claims abstract description 8
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 4
- 238000000227 grinding Methods 0.000 claims abstract description 4
- 239000001102 lavandula vera Substances 0.000 claims abstract description 4
- 235000018219 lavender Nutrition 0.000 claims abstract description 4
- 239000000341 volatile oil Substances 0.000 claims abstract description 4
- 235000010485 konjac Nutrition 0.000 claims description 11
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 10
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 10
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 10
- 241001313857 Bletilla striata Species 0.000 claims description 10
- 229920002581 Glucomannan Polymers 0.000 claims description 10
- 229940046240 glucomannan Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 6
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000000704 physical effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 abstract description 2
- 230000037314 wound repair Effects 0.000 abstract description 2
- 239000002245 particle Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 241000218176 Corydalis Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000032798 delamination Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Abstract
The invention belongs to the technical field of traditional Chinese medicine compounds, and discloses tetrahydropalmatine-bletilla polysaccharide latex and a preparation method thereof, wherein the preparation method comprises the following steps: grinding and mixing rhizoma bletilla polysaccharide and konjac gum together, and dissolving in a solvent to obtain a first mixed solution; centrifuging the first mixed solution to obtain a supernatant; uniformly mixing glycerol, triethanolamine and the supernatant, and carrying out water bath heat preservation to obtain a water phase; uniformly mixing tetrahydropalmatine, lavender essential oil and melted stearic acid to obtain an oil phase; and uniformly mixing the oil phase into the water phase, and homogenizing and emulsifying to obtain the O/W type tetrahydropalmatine-bletilla polysaccharide gel latex. In conclusion, the tetrahydropalmatine-bletilla polysaccharide gel latex prepared by the invention has good physical properties and good transdermal absorptivity, and has analgesic effect and good wound repair effect compared with other similar products. In addition, the preparation method has simple steps and low cost.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine compounds, and particularly relates to tetrahydropalmatine-bletilla polysaccharide latex and a preparation method thereof.
Background
Rhizoma corydalis, called rhizoma corydalis and rhizoma corydalis, is dry tuber of rhizoma corydalis of Papaveraceae, belongs to one of the eight ingredients of Zhejiang, has effects of promoting blood circulation, activating qi-flowing, relieving pain, etc., and can be used for treating pain syndrome due to blood stasis and qi stagnation. Modern pharmacological research shows that corydalis tuber mainly contains various chemical components such as alkaloids, steroids, organic acids and the like, and has pharmacological effects of easing pain, resisting myocardial ischemia, resisting cerebral ischemia, resisting tumor, resisting diabetes and the like. And the clinical analgesic effect of the rhizoma corydalis is proved to be remarkable, wherein the analgesic effect of tetrahydropalmatine which is one of the active ingredients of the rhizoma corydalis is strongest. At present, tetrahydropalmatine is mainly administered orally and intramuscularly, and the oral administration has a certain stimulation effect on gastrointestinal tracts and has liver first pass effect, and the intramuscular administration also has allergic conditions, so that the clinical application of tetrahydropalmatine is severely limited.
Transdermal administration is a mode that the medicinal components reach the tissues in the body through skin barriers, and compared with the traditional oral administration and subcutaneous injection, the transdermal administration can maintain constant medicinal concentration in the body to the maximum extent, is safe and simple to use, and can avoid pain and adverse reactions caused by intramuscular injection.
The bletilla polysaccharide is also called bletilla gum and bletilla mannan, is a water-soluble high-molecular viscous polysaccharide extracted from the traditional Chinese medicine bletilla, can form viscous gel after being dissolved in water, has good biological adhesiveness, and is safe and nontoxic. In addition, the composite material also has pharmacological activities such as antiulcer, antiinflammatory, procoagulant, antioxidant and the like, can be used as a carrier material of various external preparations, has higher commercial utilization value and research value, is widely applied to the fields of medical raw materials, pharmaceutical auxiliary materials, biomedical materials and the like, and has good application prospect.
In summary, the invention provides an external latex prepared from bletilla striata polysaccharide and tetrahydropalmatine.
Disclosure of Invention
In view of the above, the present invention aims to provide a tetrahydropalmatine-bletilla polysaccharide latex and a preparation method thereof.
In order to achieve the above purpose, the present invention provides the following technical solutions:
A preparation method of tetrahydropalmatine-bletilla polysaccharide latex comprises the following steps:
Grinding and mixing rhizoma bletilla polysaccharide and konjac gum together, and dissolving in a solvent to obtain a first mixed solution;
Centrifuging the first mixed solution to obtain a supernatant;
uniformly mixing glycerol, triethanolamine and the supernatant, and carrying out water bath heat preservation to obtain a water phase;
uniformly mixing tetrahydropalmatine, lavender essential oil and melted stearic acid to obtain an oil phase;
and uniformly mixing the oil phase into the water phase, and homogenizing and emulsifying to obtain the O/W type tetrahydropalmatine-bletilla polysaccharide gel latex.
Preferably:
the mixing mass ratio of the bletilla polysaccharide to the konjac glucomannan is 40-60: 1.
The triethanolamine accounts for 0.4 to 1.2 percent of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex.
The stearic acid accounts for 1-3% of the total mass of the tetrahydropalmatine-bletilla polysaccharide gel latex.
The solvent is hot purified water.
The centrifugal rotating speed of the centrifugal treatment is 3000r/min, and the centrifugal time is 5min.
The temperature of the water bath heat preservation is 70 ℃.
The homogenizing and emulsifying includes high-speed homogenizing and high-pressure homogenizing. Specifically, the high-speed homogenizing cycle is executed for 3 times, the homogenizing time is 1min each time, and the rotating speed of the high-speed homogenizing is 9000r/min; the high pressure homogenization cycle is performed 15 times, the pressure of the high pressure homogenization being 1000bar.
The invention also provides tetrahydropalmatine-bletilla polysaccharide latex prepared by the preparation method.
Compared with the prior art, the invention has the following beneficial effects:
The tetrahydropalmatine-bletilla polysaccharide gel latex prepared by the invention has good physical properties and good transdermal absorptivity, has analgesic effect and good wound repair effect compared with other similar products, and can provide new technical means and application references for further development and utilization of tetrahydropalmatine. In addition, the preparation method disclosed by the invention is simple in steps, low in cost, wide in application prospect and capable of being effectively applied to industrialized mass production.
Drawings
FIG. 1 is a liquid chromatogram of tetrahydropalmatine; ( a, a reference substance solution of tetrahydropalmatine standard substance; b sample solution of tetrahydropalmatine-bletilla polysaccharide gel latex prepared by the invention )
FIGS. 2-3 are graphs showing particle size and PDI values of tetrahydropalmatine-bletilla polysaccharide latices prepared in accordance with the present invention;
FIG. 4 is a transmission electron microscope image of tetrahydropalmatine-bletilla polysaccharide latices prepared in accordance with the present invention;
FIG. 5 is a graph comparing the results of the water loss test;
FIG. 6 is a graph comparing the results of an in vitro percutaneous absorption experiment.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The invention provides a preparation method of tetrahydropalmatine-bletilla polysaccharide gel latex, which specifically comprises the following steps:
Preparing an aqueous phase: grinding and mixing rhizoma bletilla polysaccharide and konjac gum together, and dissolving in hot purified water to obtain a first mixed solution; centrifuging the first mixed solution for 5min at a rotating speed of 3000r/min, and taking supernatant; uniformly mixing glycerol, triethanolamine and the supernatant, and carrying out water bath heat preservation at 70 ℃ to obtain a water phase.
Preparing an oil phase: heating stearic acid in 70deg.C water bath until it is completely melted, and mixing tetrahydropalmatine, lavender essential oil and melted stearic acid to obtain oil phase.
Slowly adding the oil phase into the water phase, stirring and mixing while adding, uniformly mixing, and sequentially carrying out homogenizing circulation for 3 times by using a high-speed emulsifying homogenizer 9000r/min for 1min each time and 1000bar homogenizing circulation for 15 times by using a high-pressure homogenizer to finally obtain the O/W tetrahydropalmatine-bletilla polysaccharide gel latex.
Based on the above preparation method, the following specific examples are provided
Preparing materials:
Tetrahydropalmatine (Shanghai Jizhui Biochemical technologies Co., ltd., purity 98%); bletilla striata polysaccharide (purity 98.22%); konjac gum (Shanghai source leaf biotechnology limited); triethanolamine (Shijia Heisen chemical Co., ltd.); glycerol (Seachondarium Zhejiang Huikang pharmaceutical Co., ltd.); stearic acid (Tianjin, denou chemical Co., ltd.); purifying the water.
High performance liquid chromatography (Waters-2695, waters company, usa); an evaporative light detector (Waters-2996, waters, USA) was provided; a Malvern laser particle sizer (ZEN-3600 Malvern Zeta-master, malvern Co., ltd.); a low-speed bench centrifuge (TDZ 5-WS, hunan Instrument laboratory instruments Co., ltd.); DF-101S heat collection type constant temperature heating magnetic stirrer (Henan Hehua Instrument Co., ltd.); high speed emulsion homogenizer (T18 DS25, IKA company, germany); high pressure homogenizer (ATS, an Ta si nanotechnology (su state) inc); transmission electron microscopy (H-7650, hitachi, japan); electronic precision balances (FA 2004, shanghai bridge balance works); intelligent transdermal tester (TP-6, tianjin, fine development instruments and technology Co., ltd.).
Example 1
The tetrahydropalmatine-bletilla polysaccharide latex is prepared according to the preparation method. And in this example, the triethanolamine comprises 0.8% of the total mass of the tetrahydropalmatine-bletilla polysaccharide gel latex, and the stearic acid comprises 2% of the total mass of the tetrahydropalmatine-bletilla polysaccharide gel latex.
In addition, the following formulation embodiments of bletilla polysaccharide and konjac gum are provided in this example:
In embodiment 1-1, the mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 40:1, a step of;
In embodiments 1-2, the mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 45:1, a step of;
In embodiments 1 to 3, the mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 50:1, a step of;
in embodiments 1 to 4, the mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 55:1, a step of;
in embodiments 1 to 5, the mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 60:1.
Example 2
The tetrahydropalmatine-bletilla polysaccharide latex is prepared according to the preparation method. In this embodiment, the mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 50:1, wherein the stearic acid accounts for 2% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex.
In addition, the following embodiments of the amounts of triethanolamine are also provided in this example:
embodiment 2-1, wherein the triethanolamine comprises 0.4% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex;
embodiment 2-2, wherein the triethanolamine comprises 0.6% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex;
embodiments 2-3, wherein the triethanolamine comprises 0.8% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex;
embodiments 2-4, wherein the triethanolamine comprises 1.0% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex;
embodiments 2-5, the triethanolamine comprises 1.2% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex.
Example 3
The tetrahydropalmatine-bletilla polysaccharide latex is prepared according to the preparation method. In this embodiment, the mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 50:1, wherein the triethanolamine accounts for 0.8% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex.
In addition, the following embodiments of the amounts of stearic acid are also provided in this example:
Embodiment 3-1, stearic acid comprising 1.0% of the total mass of tetrahydropalmatine-bletilla polysaccharide latex;
embodiment 3-2, stearic acid comprising 1.5% of the total mass of tetrahydropalmatine-bletilla polysaccharide latex;
embodiment 3-3, stearic acid comprising 2.0% of the total mass of tetrahydropalmatine-bletilla polysaccharide latex;
embodiments 3-4, stearic acid comprising 2.5% of the total mass of tetrahydropalmatine-bletilla polysaccharide latex;
embodiments 3-5, stearic acid comprises 3.0% of the total mass of tetrahydropalmatine-bletilla polysaccharide latex.
To sum up
One) the content of tetrahydropalmatine in the tetrahydropalmatine-polysaccharide coagulated latex (hereinafter abbreviated as coagulated latex for convenience of description) prepared in the above three examples was measured:
Measurement conditions: hypersilGOLDC 18 chromatography column (4.6 mm. Times.250 mm,5 μm); methanol-0.1% strength phosphoric acid solution (pH 6.0 with triethylamine) (55:45); the flow rate is 1.0mL/min; detection wavelength 280nm; the column temperature was 25℃at room temperature. The sample injection amount is 10 mu L, and the theoretical plate number is not less than 3000 calculated according to tetrahydropalmatine peak.
Preparing a reference substance solution: precisely weighing tetrahydropalmatine standard substance 4mg, placing in 100mL volumetric flask, adding methanol to dissolve and dilute to scale, and shaking to obtain reference substance solution containing 0.04mg per 1 mL.
Sample solution preparation: precisely sucking 0.5mL of gel emulsion, dissolving with water, fixing volume to 25mL measuring flask, shaking, passing through 0.45 μm microporous filter membrane, discarding the primary filtrate, and collecting the subsequent filtrate as sample solution.
Standard curve preparation: precisely sucking reference substance solutions of 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0mL, respectively placing into 10mL measuring flask, and diluting with methanol to scale to obtain serial reference substance solutions with the concentrations of: 2. 4, 8, 12, 16, 20, 24, 40 μg/mL. Respectively precisely sucking 10 μl of each of the reference solutions, and injecting into a liquid chromatograph to determine peak area. Specifically, referring to fig. 1a, linear regression is performed with chromatographic peak area a and reference concentration to obtain a standard linear equation y=11994x+12404, correlation coefficient r=0.9999, and tetrahydropalmatine has good linearity in the concentration range of 2-100 μg/mL.
Sample content determination: precisely sucking 10 mu L of the sample solution, injecting into a liquid chromatograph, measuring the peak area, calculating the content of tetrahydropalmatine based on a standard linear equation, measuring 3 parts and taking an average value.
And secondly), observing the appearance by adopting a naked eye observation method and a transmission electron microscope method. The particle size and PDI value were determined using a Malvern laser particle sizer. The physical stability of the material was examined by high-speed centrifugation and storage at different temperatures. The moisture retention performance is examined by adopting a water loss rate test. The skin spreadability was examined using a coating test.
(1) Particle size and PDI value
Particle size and polydispersity index (PDI) of the latex were measured using a Malvern particle size tester: 1mL of the gel milk sample was aspirated, placed in a beaker, and the sample was diluted with 50mL of purified water and shaken well (avoiding the multiple scattering effect). And (3) adding a proper amount of diluted sample into a sample cell of a Malvern particle size detector, measuring the particle size and the PDI value of the latex sample at 25 ℃, measuring for 3 times in parallel, and taking an average value.
Regarding example 1, the particle size and PDI detection results of the latex prepared in each embodiment thereof are shown in fig. 2A. As can be seen from the graph, under the condition that other conditions are fixed, the particle size and PDI value of the gel milk show a tendency of weakening before increasing with the increase of the addition ratio of bletilla polysaccharide and konjac gum. The reason is that: when the konjak gum amount is increased, the solution viscosity is increased, the emulsification effect is affected, and the particle size and the PDI value of the latex are higher; when the amount of rhizoma bletillae polysaccharide is increased, the addition amount of konjac glucomannan is correspondingly reduced, the oil-water interfacial tension is reduced, and the particle size and the PDI value of the latex are reduced; the ratio of the two is further increased, the viscosity is increased, the particle size is also increased, and the PDI value tends to be increased. In summary, m (bletilla polysaccharide) is preferred: m (konjac gum) =50: 1.
Regarding example 2, the particle size and PDI detection results of the latex prepared in each embodiment thereof are shown in fig. 2B. As can be seen from the graph, under the condition that other conditions are fixed, the particle size and the PDI value of the gel milk show a tendency of weakening before increasing with the increase of the amount of the triethanolamine. The reason is that: when the amount of triethanolamine is 0.4%, the emulsification effect is poor, the stability of the gel emulsion is affected, and the particle size and the PDI value of the gel latex are high; and when the dosage is continuously increased to 1.2%, the viscosity of the solution is increased, and the particle size and the PDI value are influenced. In summary, it is preferred that triethanolamine comprises 0.8% of the total mass of tetrahydropalmatine-bletilla polysaccharide latices.
Regarding example 3, the particle size and PDI detection results of the latex prepared in each embodiment thereof are shown in fig. 2C. As can be seen from the graph, the particle size and PDI value of the gel milk show a tendency to decrease and then increase with increasing amount of stearic acid under other conditions. The reason is that: when the consumption of stearic acid is smaller and the water phase ratio is larger, the emulsification effect is poor, so that the particle size and PDI value of the latex are increased; and excessive use of the water-based latex reduces uniformity of the latex, has a tendency of oil-water delamination, and influences particle size and PDI value of the latex. In summary, stearic acid is preferably present at 2.0% of the total mass of tetrahydropalmatine-bletilla polysaccharide latices.
In summary, at m (bletilla polysaccharide): m (konjac gum) =50: 1. as can be seen from FIG. 3, the preferable proportions of triethanolamine 0.8% and stearic acid 2.0% show that the average particle size of the coagulated latex is about 1.56. Mu.m, the distribution is uniform, and the PDI value is 0.434. As can be seen in FIG. 1b, the preferred formulation provides a tetrahydropalmatine content of 0.079% in the latex.
The following description will be made with the above preferable proportion
(2) Appearance form
Based on visual observation, the gel emulsion prepared under the preferable proportion is milky, has certain viscosity and fluidity, is fine and uniform, and has sparkling and crystal luster.
Based on transmission electron microscopy: taking a proper amount of gel emulsion sample, dripping the gel emulsion sample onto a copper mesh of a carbon film, standing for 5min, sucking away the redundant sample, cleaning with purified water for 3 times, then dripping 2.0% phosphotungstic acid solution for negative dyeing for 5min, sucking away the redundant dye solution by using filter paper, naturally airing, and then placing under a Transmission Electron Microscope (TEM) to observe the particle morphology and the particle size of the gel emulsion. As is clear from FIG. 4, most of tetrahydropalmatine particles have a spherical shape of uniform size, are free from aggregation, and have a particle diameter of about 2. Mu.m.
(3) Physical stability
Taking a proper amount of gel emulsion sample, centrifuging at 5000r/min for 15min, and no oil-water delamination is found.
4 Parts of equivalent latex samples were taken and stored at 4℃and 25℃and 40℃for 10 days, and sampled and observed at 3 days, 5 days and 10 days, respectively. No delamination of latex samples was observed during storage at 4 ℃,25 ℃, 40 ℃ and no significant change in particle size distribution; at 40 ℃, the oil-water delamination trend is seen for 10 days. Therefore, the gel milk sample has better physical stability at normal temperature.
(4) Moisture retention (Water loss rate experiment)
Two microporous filters of 0.22 μm were placed on a waterproof double-silica paper, designated as No. 1 and No.2, at 25℃and 40% humidity. And uniformly coating a proper amount of gel milk sample on the No.2 filter membrane, then dripping 5 drops of purified water on the No. 1 filter membrane and the No.2 filter membrane, weighing, and then measuring the water loss rate of the two filter membranes respectively at 5, 15, 30, 60 and 120 min. As shown in figure 5, the water loss rate of the No.2 filter membrane is obviously lower than that of the No. 1 filter membrane, so that the gel emulsion prepared by the invention has better moisturizing effect, and can improve skin elasticity and promote skin hydration, thereby increasing the percutaneous permeability of the active ingredient and enhancing pharmacological action.
(5) Skin spreadability
A proper amount of gel milk sample is taken and coated on double silicon paper (with hydrophobicity similar to skin) for observation, and the gel milk sample is found to be uniform after being coated and has no aggregation phenomenon. Based on the results, the gel emulsion prepared by the invention has good skin spreadability, and tetrahydropalmatine is dispersed in the water-soluble polymer material in the form of particles, so that the gel emulsion is favorable for being fully contacted with skin for absorption, and has the advantages of moistening, easy coating, fragrant smell, no greasy feeling and the like.
Three) in vitro transdermal absorption experiments of latex (taking latex at a preferred ratio as an example)
Preparation of ex vivo skin: taking clean SD rats (weight 190+ -20 g, male), removing hair from sternum and abdomen with shaver after neck removal, cutting abdomen skin with proper size, removing subcutaneous tissue and fat (ensuring skin cuticle is not damaged during removing process), washing with physiological saline, wrapping clean and complete skin with aluminum foil paper, freezing at-20deg.C, and storing for one week.
Preparing a transdermal receiving solution: 0.9% physiological saline and ethanol according to 80:20 to obtain a receiving solution for an in vitro percutaneous absorption test.
In vitro skin penetration investigation:
the in vitro skin penetration of the latex was examined using the Franz diffusion cell method (effective penetration area 0.785cm 2, receiving chamber volume 15 mL).
Thawing rat in vitro skin at room temperature, washing with physiological saline, shearing to proper size, fixing between supply chamber and receiving chamber of transdermal absorption device, maintaining skin flatness, adding receiving liquid into the receiving chamber with horny layer facing the supply chamber, and exhausting bubbles to make skin closely contact with the receiving liquid.
The water bath temperature (37+/-0.5) DEG C, the magnetic stirring rotating speed is 350r/min, and the balance is 20min.
Precisely measuring 0.5mL of latex, preparing a tetrahydropalmatine solution with the same concentration as a blank control, loading under the same condition, sampling 0.5mL of receiving solution at 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 hours, supplementing an equal volume of fresh receiving solution, and removing bubbles. The received solution taken out in the corresponding time is filtered by a microporous filter membrane of 0.22 mu m to obtain an experimental sample solution.
Measuring the content of tetrahydropalmatine in the experimental sample solution (chromatographic method), calculating the mass concentration of the medicament at the corresponding time, and calculating the accumulated transmission amount of the tetrahydropalmatine at the corresponding time according to the following formula:
Where Q n is the cumulative transmission per unit area (μg/cm 2) at the nth time point, V is the volume of the receiving solution (mL), 0.5 is the sampling volume (mL), S is the effective skin permeation area (cm 2),Cn is the drug mass concentration (μg/mL) in the receiving cell at the nth time point, and C i is the drug mass concentration (μg/mL) at a time point before the nth time point.
The cumulative permeation quantity-time curve shown in fig. 6 is drawn by taking the cumulative permeation quantity Q n of tetrahydropalmatine at different time points in the latex as an ordinate and the sampling time t as an abscissa. As can be seen from FIG. 6, the cumulative permeation amount increases with time, the cumulative permeation amount of tetrahydropalmatine 24h in the blank group is 198.79 mug/cm 2, and the cumulative permeation amount of tetrahydropalmatine 24h in the latex reaches 910.22 mug/cm 2, so that the in vitro transdermal absorption effect of tetrahydropalmatine can be improved to a greater extent.
In summary, the invention adopts a combination of a new soap method and a high-pressure homogenizing emulsification method to prepare tetrahydropalmatine-bletilla polysaccharide gel latex, and m (bletilla polysaccharide) in each raw material is preferably selected: m (konjac gum) =50: 1. triethanolamine was added at 0.8% and stearic acid was added at 2.0%. Based on the preferable proportion, the average grain diameter of the obtained tetrahydropalmatine-bletilla polysaccharide gel latex is about 1.56 mu m, the PDI is 0.434, the appearance is uniform and fine and smooth, the adhesive and the fluidity are good, the coating is easy, the moisture retention is good, and the physical stability and the in-vitro transdermal absorption effect are good, so that a new technical means is provided for the application of tetrahydropalmatine, and the application prospect is wide.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. A method for preparing tetrahydropalmatine-bletilla polysaccharide latex, which is characterized by comprising the following steps:
Grinding and mixing rhizoma bletilla polysaccharide and konjac gum together, and dissolving in a solvent to obtain a first mixed solution;
Centrifuging the first mixed solution to obtain a supernatant;
uniformly mixing glycerol, triethanolamine and the supernatant, and carrying out water bath heat preservation to obtain a water phase;
uniformly mixing tetrahydropalmatine, lavender essential oil and melted stearic acid to obtain an oil phase;
Uniformly mixing the oil phase into the water phase, and homogenizing and emulsifying to obtain O/W type tetrahydropalmatine-bletilla polysaccharide gel latex;
The mixing mass ratio of the bletilla striata polysaccharide to the konjac glucomannan is 50:1, a step of;
the triethanolamine accounts for 0.8% of the total mass of the tetrahydropalmatine-bletilla polysaccharide latex;
the stearic acid accounts for 2% of the total mass of the tetrahydropalmatine-bletilla polysaccharide gel latex.
2. The method of manufacturing according to claim 1, characterized in that: the solvent is hot purified water.
3. The method of manufacturing according to claim 1, characterized in that: the centrifugal rotating speed of the centrifugal treatment is 3000r/min, and the centrifugal time is 5min.
4. The method of manufacturing according to claim 1, characterized in that: the temperature of the water bath heat preservation is 70 ℃.
5. The method of manufacturing according to claim 1, characterized in that: the homogenizing and emulsifying includes high-speed homogenizing and high-pressure homogenizing.
6. The method of manufacturing according to claim 5, wherein: the high-speed homogenizing cycle is executed for 3 times, the homogenizing time is 1min each time, and the rotating speed of the high-speed homogenizing is 9000r/min; the high pressure homogenization cycle is performed 15 times, the pressure of the high pressure homogenization being 1000bar.
7. A tetrahydropalmatine-bletilla polysaccharide latex prepared by the method of any one of claims 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310067982.5A CN115969777B (en) | 2023-01-30 | Tetrahydropalmatine-bletilla polysaccharide latex and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310067982.5A CN115969777B (en) | 2023-01-30 | Tetrahydropalmatine-bletilla polysaccharide latex and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115969777A CN115969777A (en) | 2023-04-18 |
| CN115969777B true CN115969777B (en) | 2024-07-05 |
Family
ID=
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178661A (en) * | 2011-04-21 | 2011-09-14 | 浙江省医学科学院 | Levo-tetrahydropalmatine transdermal drug delivery preparation |
| CN113908139A (en) * | 2021-10-29 | 2022-01-11 | 贵州中医药大学 | Preparation method of corydalis tuber total alkaloid gel paste |
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178661A (en) * | 2011-04-21 | 2011-09-14 | 浙江省医学科学院 | Levo-tetrahydropalmatine transdermal drug delivery preparation |
| CN113908139A (en) * | 2021-10-29 | 2022-01-11 | 贵州中医药大学 | Preparation method of corydalis tuber total alkaloid gel paste |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112315846B (en) | Schizophyllum commune polysaccharide liposome and preparation method and application thereof | |
| CN113577125B (en) | A Chinese medicinal ointment with antiinflammatory effect, and its preparation method | |
| CN112022919A (en) | Percutaneous-absorption artemisia vulgaris oil carrier gel and preparation method thereof | |
| CN102133245B (en) | Brucea javanica oil obtained by reducing content of protein, and medicine composite and preparation method thereof | |
| CN115969777B (en) | Tetrahydropalmatine-bletilla polysaccharide latex and preparation method thereof | |
| CN110721109A (en) | Preparation method of protein liposome FNL and application thereof in cosmetics | |
| CN110559258A (en) | Tetrahydroberberine gel, preparation method thereof and transdermal rate detection method | |
| CN115969777A (en) | Tetrahydropalmatine-rhizoma bletillae polysaccharide gel emulsion and preparation method thereof | |
| CN115737561A (en) | Compound dihydric alcohol plastid, preparation method and application thereof | |
| CN106983789B (en) | Compound phellodendron bark liquid transdermal absorption preparation and preparation method and application thereof | |
| CN113197944B (en) | Compound lithospermum microemulsion temperature-sensitive in-situ gel and preparation method and application thereof | |
| CN110812249B (en) | Glabridin cubic liquid crystal nanoparticles and application thereof in resisting skin photodamage | |
| CN105106106B (en) | A kind of preparation method of Vaccarin ointment | |
| CN111214385A (en) | Nanoparticle emulsion loaded with skin nutrient and preparation method thereof | |
| CN111329838B (en) | Paclitaxel liposome pharmaceutical composition and preparation method thereof | |
| CN114159554A (en) | Preparation method and application of fibronectin-polyvinyl alcohol microspheres | |
| CN105832657B (en) | A kind of compound lactic acid emulsifiable paste, preparation method and application | |
| CN113144220B (en) | Beta-cyclodextrin inclusion compound, gel preparation, preparation method and application thereof | |
| CN115487137B (en) | A topical composition for relieving itching | |
| CN115501268B (en) | Gel containing fennel extract and preparation method thereof | |
| CN115137784B (en) | Wind-dispelling itching-relieving microemulsion and preparation method thereof | |
| CN114522116B (en) | Hesperidin liposome gel and preparation method and application thereof | |
| CN114931556B (en) | Preparation method of cattail pollen charcoal formula particles | |
| CN108918737B (en) | Pretreatment method and high performance liquid chromatography method for determining alkannin in W/O type lithospermum skin milk | |
| CN116983312B (en) | Pharmaceutical composition, external preparation, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |